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AbstractMultiple Sclerosis (MS) is one of several diseases described as demyelinating because it causes damage to the myelin sheath. The presence of additional medical conditions like pregnancy, osteoporosis and infections are common with multiple sclerosis that adversely affects the health outcomes. The treatment of MS becomes more complex when compounded by these existing additional medical conditions. This review highlight important pharmacotherapeutic considerations in treatment of MS in these special patient population.
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1.  Introduction
Multiple Sclerosis (MS) is a multifactorial CNS disease 
characterized by a relapsing-remitting course and 
continual accumulation of neurologic deficits. This 
disease affects more than 2 million people worldwide, 
primarily women, with onset occurring in young adults 
(age 20–40 years). The etiology of the disease is unknown 
but considered to be a combination of environmental 
and genetic factors. Risk factors for MS include Epstein-
Barr virus, low concentrations of vitamin D, obesity, 
mononucleosis, increased sodium intake, and cigarette 
smoking1.
Multiple sclerosis is potentially triggered by an 
autoimmune process that affects the CNS. The disease 
causes inflammation of both white and grey matter. 
The typical features of MS are widespread areas 
of demyelination noted as plaques or lesions2. Re-
myelination occurs over several months after lesion 
formation and is extremely variable between patients and 
in different plaques within the same patient. The process 
becomes slower over time as the disease progresses. Re-
myelination is highly inefficient and does not lead to full 
axonal integrity, thus leading to disease progression1. The 
specific management questions and concerns surround in 
patients with special conditions. This is complicated by the 
fact that MS has entered a treatment era. Unfortunately, 
there are no recognized and implemented guidelines. The 
present review highlight important pharmacotherapeutics 
considerations in unique situations of multiple sclerosis.
2.  Pregnancy
Multiple sclerosis predominately affects women and often 
has a clinical onset during childbearing years. Therefore, 
for women with child bearing potential diagnosed with 
MS, reproduction is an important consideration. The 
effect of pregnancy on relapse risk of MS is the most 
studied aspect. Studies have shown that the relapse rate 
over the whole pre-pregnancy to post-pregnancy period 
appears to be identical to that of the nonpregnant state. In 
the recent past, pregnancy has been reported to have both 
negative effects or benefit to maternal MS progression. 
Women with progressive forms of MS are less likely to 
have children, creating a limitation in this area of study. 
In these women change in fertility rates have not been 
demonstrated by reliable studies. 
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Individuals who wish to have children should 
be encouraged to consider strategies to increase the 
probability of conceiving during the period they are 
relatively healthy and not taking any Disease Modifying 
Treatments (DMTs)3. Another concern for women with 
MS is the risk of transmission of disease to their children. 
Compared to general population, offspring of women 
with MS have a 20–50 times greater risk of developing 
MS, although the absolute risk is relatively low4,5.
Glatiramer acetate (FDA pregnancy category B) does 
not appear to be associated with teratogenic risk or a 
higher risk of miscarriage6. Fingolimod is classified as 
FDA category C (i.e., animal studies warrant patients be 
counselled on foetal risk and appropriate contraception use 
for at least 2 months after stopping the drug). Natalizumab 
is also FDA category C based on the lack of human 
data6. Mitoxantrone and teriflunomide are associated 
with teratogenic effects and should only be prescribed 
to women who are using reliable contraception7,8. Based 
on the available literature, glatiramer acetate is the 
safest option during pregnancy if a DMT is necessary6. 
Typically, patients are counselled on stopping their DMTs 
immediately before and during pregnancy. 
Experts generally recommend a 2–6-week 
discontinuation of therapy before attempting to conceive, 
with the exception of fingolimod and teriflunomide. 
Fingolimod may take up to 2 months to be cleared, and 
teriflunomide can take up to 2 years. If a man or woman 
is considering starting a family, cholestyramine 8 g 
every 8 hours for 11 days should be admin-istered after 
discontinuation of teriflunomide. Contraceptives must 
be continued as long as the teriflunomide serum con-
centration is greater than 0.02 mg/L9.
A serious MS relapse generally treated by 
either intravenous corticosteroids or intravenous 
immunoglobulin (IVIG). Steroids increase the risk 
of preeclampsia, premature rupture of membrane, 
maternal hypertension and infections. Intravenous 
immunoglobulin has no known teratogenic effects and 
appears to have no effects on the immune system of 
the foetus. The optimal timing of restarting therapy or 
initiating breastfeeding is unclear. Research has shown 
interferon-beta, glatiramer acetate, and natalizumab to 
be moderately safe during breastfeeding. However, with 
the limited information available, women should not 
resume therapy until after breastfeeding. For lactating 
mothers, corticosteroids or IVIG are the options for 
relapse prevention or treatment. Monthly corticosteroids 
have been used to reduce the risk of postpartum relapses 
because corticosteroids are relatively safe to use but do 
have adverse effects in children10. It is recommended 
to suspend breastfeeding for 4 hours after infusion of 
a corticosteroid with a “pump and dump” approach. 
Maternal IVIG use does not seem to have detrimental 
effects on the infant4,11.
3.  Osteoporosis
Osteoporosis is more common in patients with MS than 
the general population. Reasons for this increased risk 
include the use of corticosteroids, immobility, and the 
increased probability of falls because of gait difficulties. 
Multiple sclerosis has also been associated with low 
amounts of vitamin D and smoking, two additional 
risk factors for osteoporosis. Interferon-beta may have 
favourable effect on bone metabolism in patients with MS, 
probably because of the inhibitory effect of interferon-
beta on osteoclasts12. The Fracture Risk Assessment Tool 
(FRAX) tool is routinely used in practice to establish 
the risk of osteoporosis-related fractures; however, 
it likely underestimates the risk in patients with MS 
because co-morbidity is not used in calculating fracture 
risk. Regardless, the reduction in bone mineral density 
may have already started at the time of initial clinical 
presentation. Therefore, patients should be proactive to 
ensure optimal bone health13.
4.  Dietary Considerations
Dietary interventions can favourably influence 
MS; proposed interventions included diets high in 
polyunsaturated fats and low in animal fats, gluten-free, 
sucrose-free, pectin-restricted diets, and the Paleo diet. 
Vitamin B12 deficiency may lead to deformed myelin 
and is associated with immunomodulatory activities. 
Low concentrations of vitamin B12 have been reported in 
patients, but a relationship between vitamin B12 and MS 
has yet to be confirmed14. Supplements with antioxidant 
activity (vitamin A, C, E and Co-enzyme Q 10) may 
decrease free radical–induced cellular injury, which may 
con-tribute to myelin and axonal injury15.
Omega-3 fatty acids may have clinical and biochemical 
effects in patients with MS. This supplement may 
Vol 8 (3) | 2016 | www.informaticsjournals.com/index.php/ajprhc Asian Journal of Pharmaceutical Research and Health Care74
Some Unique Considerations in Treatment of Multiple Sclerosis
have anti-inflammatory, antithrombotic, antioxidant, 
immuno-modulatory functions, as well as neuroprotective 
effects16,17. Because increased oxidative damage has been 
associated with disease progression, a reduction of pro-
inflammatory cytokines and oxidative stress could benefit 
patients. Taking 4 gram of fish oil daily has been shown to 
reduce inflammatory cytokine concentrations. However, 
the supplement has not been proved to reduce relapse 
rates, disability progression, or fatigue15. 
Vitamin D has been linked to the risk of developing 
MS through evidence demonstrating that individuals with 
MS have lower levels of 25-hydroxyvitamin D relative to 
healthy controls18. Bioactive vitamin D may modulate 
the production of neurotrophins, growth factors, and 
neurotransmitters, as well as the induction of nerve 
growth factor syntheses. Several studies investigating the 
effect of vitamin D to modify the course of MS have had 
inconclusive results18. More evidence favours vitamin D 
supplementation as a preventive measure in developing 
MS. The optimal dosage and age to target using vitamin D 
supplementation remains unclear. 
5.  Immunization
Evidence has suggested that MS exacerbations occur 
because of infectious episodes, some of which may be 
prevented by vaccination. However, concerns about the 
safety of vaccinating patients with MS remain19. The 
immunization panel of Consortium of Multiple Sclerosis 
Centers in collaboration with American Academy 
of Neurology, published a summary of evidence and 
recommendations regarding immunizations and MS. 
Hepatitis B, inactivated influenza and tetanus vaccines are 
safe for patients with MS. In general, inactivated vaccines 
are considered safe; however, live attenuated vaccines 
are not recommended with the exception of live zoster 
vaccine. Live Varicella vaccine should be considered 
in a patient who has never had Varicella Zoster Virus 
(VZV) infection, lacks evidence of prior immunity, or 
is considering starting an MS therapy that suppresses 
cell-mediated immunity. Pneumococcal vaccine is safe 
for patients with MS. Immunization with the VZV live 
virus vaccine should be given 2 months before initiating 
fingolimod, regardless of whether a patient is receiving an 
immunomodulatory DMT.
If a patient is experiencing a serious relapse, vaccination 
should be deferred until 1-2 months after the onset of 
relapse. Patients on chronic corticosteroid treatment 
should consult with their neurologist before taking a 
live vaccination. If a close family member receives a live 
vaccine, a neurologist should be consulted regarding what 
precautions the patient with MS on immunosuppressant 
therapy should take20.
6.  Oral Hygiene
Having MS can affect the ability of patients to maintain 
oral hygiene, preventive maintenance and seeking dental 
care. Patients with paraesthesia in arms and hands 
will have a decreased ability to carry out adequate oral 
hygiene. Many drugs used to treat MS have adverse 
effects such as gingival hyperplasia, xerostomia, and 
stomatitis; oral vigilance is therefore necessary in these 
patients. It is optimal that the dental treatment should 
be performed when the patients’ disease is in remission 
state. Appointments should be scheduled more often, for 
shorter durations, and in the morning, all of which reduce 
stress in the patient with neurologic problems.
7.  Conclusion 
An integrated multidisciplinary health care team 
approach is essential in the management of MS in special 
patient population. Appropriate selection and evaluation 
of pharmacotherapy is crucial.  Careful selection of 
treatment options, encouraging modification of risk 
factors and providing contraceptive and preconception 
counselling are all important contributions to care which 
can maximize the treatment outcomes and help patients 
set realistic expectations about their MS treatment. 
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